Stock Market Reviews

Read and share opinions on SXTP (60 Degrees Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stoc

Latest News

• 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
  Nov 13, 2025
• 60 Degrees Pharmaceuticals and NDT Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  Oct 31, 2025
• 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
  Oct 9, 2025
• Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22
  Oct 2, 2025
• Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  Sep 19, 2025
• 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
  Sep 3, 2025
• 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
  Aug 21, 2025
• 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
  Aug 19, 2025
• 60 Degrees Pharmaceuticals Second Quarter 2025 Earnings: Revenues Disappoint
  Aug 18, 2025
• 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
  Aug 13, 2025
• Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  Aug 8, 2025
• 60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria
  Jul 17, 2025
• 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering
  Jul 16, 2025
• 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
  Jul 15, 2025
• 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion
  Jul 15, 2025
• 60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
  Jul 14, 2025
• 60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  Jun 6, 2025